In the IMPT treatment plans calculated in this study, the CTV dose coverage was only slightly affected by setup errors and range errors. The OARs appeared to be more sensitive for the introduced uncertainties, with a potentially significant increase of dose to the OARs.
Purpose/Objective: To investigate the dosimetric feasibility of a two-steps dose escalation strategy in patients affected by Malignant Pleural Mesothelioma (MPM) by using Helical Tomotherapy (HT). Materials and Methods: Twelve patients with MPM, treated using HT, were selected. The prescribed median doses to the planning target volume (PTV) boost, outlined by the FDG-PET/CT and to the PTV (pleural cavity) were 61.6 Gy (range 60-66 Gy) and 54 Gy (range 50.4-54 Gy) in 28-30 fractions, respectively. PTVs and Organs At Risk (OAR) were contoured by physicians according to institutional protocols. Inverse planning optimization was performed using the following parameters: Field Width = 2.5 cm, pitch = 0.287, final Modulation Factor ranged between 1.8 and 2.3. For each patient two dose escalation plans were generated prescribing 62.5 Gy and 70 Gy (2.5 and 2.8Gy/fraction respectively) to the PTV boost and 56 Gy (2.24 Gy/fraction) to the PTV pleural cavity in 25 fractions. For the three treatment planning strategies, for each patient, the average dose to controlateral lung, lungs sum, liver, heart, esophagus, kidneys and small bowel were evaluated. QUANTEC Dose Volume Histograms (DVH) constraints were used for planning evaluation. The statistically difference among plans was tested by Mann-Whitney non parametric test (MedCalc statistics Software). Results: For all plans, the 95% PTV Volumes received at least the 95% of the prescribed dose. For all the considered OARs, the dosimetric constraints investigated are reported in figure 1. For all plan strategies the average dose to the controlateral lung was always below 8 Gy. There was no dosimetric statistically significant difference between approved and 2.5 Gy/fr (p>0.05) while a significant dosimetric difference between approved and 2.8 Gy/fr average doses of OARs 3rd ESTRO Forum 2015 S599 investigated (except for kidney) was observed. However, the QUANTEC constraints for all plans and OARs were satisfied. Conclusions: The results of this study seem to demonstrate that it is possible to safely perform a dose escalation ensuring ICRU PTV indication criteria coverage and satisfying all QUANTEC constraints.
PO-1106
Dosimetric impact to organs at risk when the internal mammary node chain is included in irradiation of left breast G. Gómez de Segura Melcón 1 , X. Nolla 1 , S. Bermejo 2 , N. Ventosa 2 , J. Isern 2 , P. Carrasco 1 Purpose/Objective: Recent EORTC studies report an increase in survival in breast cancer patients treated with RT when the internal mammary node (IMN) is included. The aforementioned studies were based on conventional 3D irradiation with photons in breast and supraclavicular and axillary nodes and a direct electron field in the IMN. To our knowledge, the safety of including IMN in IMRT has not been studied to date. The objective of the study was to retrospectively evaluate the dosimetric impact on the usual organs at risk (OAR) in the irradiation of the left breast/chest wall (heart, lungs, and contralateral breast) treated with IMRT.
Materials and Methods:
We selected all breast patients (n = 30) treated with IMRT (left breast, left chest wall, with/without nodes and with/without boost) in 2014. CT planning was performed in all patients with a Philips Big Bore CT. We defined the volumes to irradiate and the OAR. We performed a new IMRT planning to compare with the previous technique. We used our standard distribution of fields in each case. Treatment planning and volume definition were defined using the Eclipse V8.9 planning system from Varian. After optimizing dosimetry to obtain the best coverage and homogeneous distribution of PTVs, we compared the dose received in OAR for each of the 2 plans, considering the constraints of our service (mainly based in QUANTEC), which are: -Heart: V30<30%; V25<15; Dmean<10Gy -Lung: V5<60%; V20<30% -Ipsilateral Lung: V20<30% -Contralateral Lung: V5<40% -Contralateral Breast: V5<2% (This is an orientation constraint because heart and lung area priority constraint). We recorded the values of these indexes for IMRT with and without IMN. Results: Table 1 shows the mean values recorded for IMRT with and without IMN, and the differences between the two plans. We found a slight increase in dose in OAR when IMN was included, but this increase did not exceed the limits established in our service.
Conclusions: IMN irradiation of the left breast can be safely performed with the new treatment techniques (IMRT) because it does not significantly increase the dose received by the OAR.
PO-1107
Comparative analysis of VMAT plans for prostate cancer with different MLCs, Elekta Agility and MLCi2 M. Hori 1 , M. Someya 1 , K. Nakata 1 , M. Kitagawa 1 , T. Hasegawa 1 , T. Tsuchiya 1 , T. Gocho 1 , Y. Fukushima 1 , Y. Takada 1 , K. Sakata 1 1 Sapporo Medical University, Department of Radiology, Sapporo, Japan Purpose/Objective: The aim of this study was to compare the various dosimetric parameters of volumetric-modulated arc therapy (VMAT) for prostate cancer using a 160-leaf multileaf collimator (5mm-leaf, Agility) with VMAT using 80 MLC (10mm-leaf, MLCi2). Monitor units and number of control points among those MLCs were also evaluated. Materials and Methods: Single-arc VMAT plans with Agility and MLCi2 were compared for 10 low to intermediate risk prostate cancer patients. Clinical target volume included the prostate and the proximal seminal vesicles. The planning target volume (PTV) was defined as CTV with a margin of 5mm posterior and 8mm in other directions. The mean dose to PTV was 76 Gy delivered in 38 fractions. Rectums were contoured as solid organs from anal verge to sigmoid flexure. The dosimetric parameters of VMAT plans with Agility and MLCi2 were calculated in a Monaco treatment planning system for Elekta Synergy linac with Monte Carlo algorithm. The parameters for PTV were the near minimum dose (D98), the near maximum dose (D2), heterogeneity Index (HI) and conformity Index (CI). The parameters for rectum were V70, V60, V50 and V40. Monitor units and control points were also evaluated. Statistical analysis to evaluate the differences two categories was performed by the paired, two-tailed Student's t-test. Results:The mean PTV was 110.8 cc (range 70.0 to 229.4 cc). The mean volume of rectum was 41.9 cc (range 26.6 to 57.1 cc). The average of the near minimum dose of PTVs (D98) were 71.9 Gy in Agility and 71.6 Gy in MLCi2 (P=0.02). The average of the near maximum dose of PTVs (D2), HI and CI were similar results among those MLCs. For rectum, the average of V70, V60, V50 and V40 in Agility were 8.56 %, 18.7 %, 27.7% and 37.8%, respectively. The average of those parameters in MLCi2 were 8.72 %, 19.8 %, 29.9 % and 41.3 %, respectively. The average of V60, 50 and 40 in Agility was significantly better than those in MLCi2 (P=0.005-0.014). The average MUs were 452.8 in Agility and 416.9 in MLCi2, respectively, which showed significantly differences
